false
0001860871
0001860871
2024-01-31
2024-01-31
0001860871
LGSTU:UnitsEachConsistingOfOneClassOrdinaryShareParValue0.0001PerShareAndOnehalfOfOneRedeemableWarrantMember
2024-01-31
2024-01-31
0001860871
LGSTU:ClassOrdinarySharesParValue0.0001PerShareIncludedAsPartOfUnitsMember
2024-01-31
2024-01-31
0001860871
LGSTU:RedeemableWarrantsEachExercisableForOneClassOrdinaryShareFor11.50PerShareIncludedAsPartOfUnitsMember
2024-01-31
2024-01-31
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): January 31, 2024
Semper
Paratus Acquisition Corporation
(Exact
name of registrant as specified in its charter)
Cayman
Islands |
|
001-41002 |
|
N/A |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
767
Third Avenue, 38th Floor
New York, New York 10017 (Address of principal executive offices, including zip code)
Registrant’s
telephone number, including area code: (646) 807-8832
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☒ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of Each Class |
|
Trading
Symbol(s) |
|
Name
of Each Exchange on Which Registered |
Units,
each consisting of one Class A ordinary share, par value $0.0001 per share, and one-half of one Redeemable Warrant |
|
LGSTU |
|
The
Nasdaq Stock Market LLC |
Class
A ordinary shares, par value $0.0001 per share, included as part of the Units |
|
LGST |
|
The
Nasdaq Stock Market LLC |
Redeemable
warrants, each exercisable for one Class A ordinary share for $11.50 per share, included as part of the Units |
|
LGSTW |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
5.07 Submission of Matters to a Vote of Security Holders.
On
January 31, 2024, Semper Paratus Acquisition Corporation, a Cayman Islands exempted company (“Semper Paratus”) held an extraordinary
general meeting of the shareholders (the “Meeting”), which was called to approve the proposals relating to the entry into
and consummation of the Agreement and Plan of Merger, dated as of June 28, 2023 (the “Merger Agreement”) by and among Semper
Paratus, Semper Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Semper Paratus (“Merger Sub”),
Tevogen Bio Inc, a Delaware corporation (“Tevogen Bio”), SSVK Associates, LLC, a Delaware limited liability company,
and Ryan Saadi in his capacity as seller representative. Pursuant to the Merger Agreement, prior to the closing of the transactions
contemplated by the Merger Agreement (the “Closing”), Semper Paratus will be continued and deregistered from the Cayman Islands,
redomesticate as a Delaware corporation and change its name to “Tevogen Bio Holdings Inc.”) (the “Domestication”),
and at the Closing, Merger Sub will merge with and into Tevogen Bio, with Tevogen Bio being the surviving company (the “Merger,”
together with the other transactions contemplated by the Merger Agreement, the “Business Combination”) and wholly-owned
subsidiary of Semper Paratus. Following the Domestication, Semper Paratus will be referred to herein as “New Tevogen.”
An
aggregate of 13,984,089 ordinary shares of Semper Paratus, that were entitled to vote as of the record date of January 4, 2024,
were represented in person or by proxy at the Meeting. Accordingly, a quorum was present and the Meeting was lawfully convened for conducting
the business to be presented at the Meeting.
Each
of the proposals presented at the Meeting was approved, and the Business Combination is expected to be consummated as soon as practicable
following the satisfaction or waiver of the remaining closing conditions described in Semper Paratus’ definitive proxy statement
for the Meeting, which
was filed with the U.S. Securities and Exchange Commission (the “SEC”) on January 10, 2024, as supplemented by a Supplement
No. 1 filed on January 24, 2024 and Supplement No. 2 filed on January 24, 2024 (the “Proxy Statement/Prospectus”), including
the condition that the common stock of
New Tevogen will have been approved for listing on a tier of The Nasdaq Stock Market. Following the Closing, New Tevogen’s common
stock is expected to begin trading on a tier of
The Nasdaq Stock Market under the proposed symbols “TVGN” and “TVGNW,” respectively.
In
connection with the Meeting, shareholders holding 1,432,457 Semper
Paratus’ Class A ordinary shares (the “Public Shares”) exercised their right to redeem their shares for a pro rata
portion of the funds in Semper Paratus’ trust account (the “Trust Account”). The trustee of the Trust Account is calculating
the final amount of the funds to be removed from the Trust Account in connection with such redemptions, but the current preliminary calculations
are that approximately $15.9 million
(approximately $11.07 per
Public Share) will be removed from the Trust Account to pay such holders. Semper Paratus will amend this Form 8-K (or file a new Form
8-K) should the actual amounts materially differ from the foregoing estimated amounts.
Semper
Paratus’ shareholders voted on the following proposals at the Meeting (the “Proposals”), each of which was approved:
(1)
Proposal No. 1 — The Business Combination Proposal — The approval of the Business Combination Proposal required the affirmative
vote of a majority of the votes cast by holders of Semper Paratus’ ordinary shares present in person or represented by proxy and
entitled to vote at the Meeting. The following is a tabulation of the votes with respect to this proposal, which was approved by Semper
Paratus’ shareholders:
For |
|
Against |
|
Abstain |
|
Broker
Non-Votes |
|
|
13,840,594 |
|
|
143,495 |
|
|
0 |
|
|
n/a |
|
(2)
Proposal No. 2 — The Domestication Proposal — The approval of the Domestication Proposal required the affirmative vote
of two-thirds (2/3) of the votes of the votes cast by holders of Semper Paratus’ ordinary shares present in person or represented
by proxy and entitled to vote at the Meeting. The following is a tabulation of the votes with respect to this proposal, which was approved
by Semper Paratus’ shareholders:
For |
|
Against |
|
Abstain |
|
Broker
Non-Votes |
|
|
13,840,594 |
|
|
143,495 |
|
|
0 |
|
|
n/a |
|
(3)
Proposal No. 3 — The Organizational Documents Proposal — The approval of the Organizational Documents Proposal required
the affirmative vote of two-thirds (2/3) of the votes of the votes cast by holders of Semper Paratus’ ordinary shares present in
person or represented by proxy and entitled to vote at the Meeting. The following is a tabulation of the votes with respect to this proposal,
which was approved by Semper Paratus’ shareholders:
For |
|
Against |
|
Abstain |
|
Broker
Non-Votes |
|
|
13,840,594 |
|
|
143,495 |
|
|
0 |
|
|
n/a |
|
(4)
Proposal No. 4 — The Advisory Charter Proposals — The approval of the Advisory Charter Proposals required the affirmative
vote of a majority of the votes cast by holders of Semper Paratus’ ordinary shares present in person or represented by proxy and
entitled to vote at the Meeting. The following is a tabulation of the votes with respect to this proposal, which was approved by Semper
Paratus’ shareholders. What follows are tabulations of the results of each of these proposals:
| (A) | A
proposal to increase the authorized share capital of Semper Paratus to 800,000,000 shares
of common stock, par value $0.0001 per share, of New Tevogen and 20,000,000 shares of preferred
stock, par value $0.0001 per share, of New Tevogen: |
For |
|
Against |
|
Abstain |
|
Broker
Non-Votes |
|
|
13,840,594 |
|
|
143,495 |
|
|
0 |
|
|
n/a |
|
| (B) | A
proposal to provide the alteration of authorized shares of New Tevogen requires the affirmative
vote of the holders of a majority New Tevogen’s stock authorized to vote: |
For |
|
Against |
|
Abstain |
|
Broker
Non-Votes |
|
|
13,840,594 |
|
|
143,495 |
|
|
0 |
|
|
n/a |
|
| (C) | A
proposal to permit removal of a director only for cause and only by the affirmative vote
of the holders of at least two-thirds (2/3) entitled to vote at an election of directors
of New Tevogen: |
For |
|
Against |
|
Abstain |
|
Broker
Non-Votes |
|
|
13,840,594 |
|
|
143,495 |
|
|
0 |
|
|
n/a |
|
| (D) | A
proposal to provide that, subject to the rights of holders of any series of preferred stock,
the number of directors will be fixed from time to time by a majority of the board of directors
of New Tevogen: |
For |
|
Against |
|
Abstain |
|
Broker
Non-Votes |
|
|
13,840,594 |
|
|
143,495 |
|
|
0 |
|
|
n/a |
|
| (E) | A
proposal to eliminate the ability of New Tevogen stockholders to take action by written consent
in lieu of a meeting: |
For |
|
Against |
|
Abstain |
|
Broker
Non-Votes |
|
|
13,840,594 |
|
|
143,495 |
|
|
0 |
|
|
n/a |
|
| (F) | A
proposal to provide that the Proposed Bylaws may be amended, altered, repealed or adopted
either by the affirmative vote of a majority of the New Tevogen Board then in office or by
the approval of at least a majority of the voting power of all of the then-outstanding shares
of voting stock: |
For |
|
Against |
|
Abstain |
|
Broker
Non-Votes |
|
|
13,840,594 |
|
|
143,495 |
|
|
0 |
|
|
n/a |
|
| (G) | A
proposal to provide that Proposed Charter may be amended, altered, repealed or adopted by
the approval of at least two-thirds (2/3) of the voting stock of New Tevogen for amendments
relating to: classification and election of the Board, removal of directors from office,
and filling vacancies on the Board; exculpation of personal liability of a director of and
indemnification of directors or officers; and amendments to the Proposed Bylaws: |
For |
|
Against |
|
Abstain |
|
Broker
Non-Votes |
|
|
13,840,594 |
|
|
143,495 |
|
|
0 |
|
|
n/a |
|
| (H) | A
proposal to provide that the Court of Chancery for the State of Delaware will be the sole
and exclusive forum for certain stockholder actions and the federal district courts of the
United States shall be the exclusive forum for claims arising out of the Securities Act of
1933: |
For |
|
Against |
|
Abstain |
|
Broker
Non-Votes |
|
|
13,840,594 |
|
|
143,495 |
|
|
0 |
|
|
n/a |
|
| (I) | A
proposal to eliminate certain provisions related to Semper Paratus’ status as a blank
check company, and allow it to continue as a corporate entity following the Business Combination: |
For |
|
Against |
|
Abstain |
|
Broker
Non-Votes |
|
|
13,840,594 |
|
|
143,495 |
|
|
0 |
|
|
n/a |
|
(5)
Proposal No. 5 — The Nasdaq Proposal — The approval of the Nasdaq Proposal required the affirmative vote of a
majority of the votes cast by holders of Semper Paratus’ ordinary shares present in person or represented by proxy and entitled
to vote at the Meeting. The following is a tabulation of the votes with respect to this proposal, which was approved by Semper Paratus’
shareholders:
For |
|
Against |
|
Abstain |
|
Broker
Non-Votes |
|
|
13,840,594 |
|
|
143,495 |
|
|
0 |
|
|
n/a |
|
(6)
Proposal No. 6 — The Omnibus Incentive Plan Proposal — The approval of the Omnibus Incentive Plan Proposal required
the affirmative vote of a majority of the votes cast by holders of Semper Paratus’ ordinary shares present in person or represented
by proxy and entitled to vote at the Meeting. The following is a tabulation of the votes with respect to this proposal, which was approved
by Semper Paratus’ shareholders:
For |
|
Against |
|
Abstain |
|
Broker
Non-Votes |
|
|
13,840,594 |
|
|
143,495 |
|
|
0 |
|
|
n/a |
|
(7)
Proposal No. 7 — The Election of Directors Proposal — The approval of the Election of Directors Proposal required
the affirmative vote of a majority of the votes cast by holders of Semper Paratus’ ordinary shares present in person or represented
by proxy and entitled to vote at the Meeting. The following is a tabulation of the votes with the elected directors to serve as Class
I, Class II, and Class III directors:
Director Nominee | |
Votes For | |
Votes Withheld | |
Broker Non-Votes |
Dr. Curtis Patton (Class I) | |
13,840,594 | |
143,495 | |
n/a |
Jeffrey Feike (Class I) | |
13,840,594 | |
143,495 | |
n/a |
Surendra Ajjarapu (Class II) | |
13,840,594 | |
143,495 | |
n/a |
Victor Sordillo (Class II) | |
13,840,594 | |
143,495 | |
n/a |
Dr. Keow Lin Goh (Class II) | |
13,840,594 | |
143,495 | |
n/a |
Dr. Ryan Saadi (Class III) | |
13,840,594 | |
143,495 | |
n/a |
Susan Podlogar (Class III) | |
13,840,594 | |
143,495 | |
n/a |
(8)
Proposal No. 8 — The Adjournment Proposal — Because Semper Paratus’ shareholders approved Proposals 1 through 7, an eighth proposal to adjourn the Meeting for the purpose of soliciting additional proxies was not submitted to Semper
Paratus shareholders for approval at the Meeting.
No
other items were presented for shareholder approval at the Meeting.
Item
7.01 Regulation FD Disclosure.
On
February 1, 2024, Semper Paratus issued a press release regarding the matters discussed in Item 5.07, a copy of which is
attached hereto as Exhibit 99.1.
The
information in this Item 7.01 and in Exhibit 99.1 attached hereto is furnished pursuant to the rules and regulations of the SEC and shall
not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”)
or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities
Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Cautionary
Statement Regarding Forward-Looking Statements
The
information in this Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, that reflect Tevogen Bio’s and Semper Paratus’ current views with respect to, among other
things, the future operations and financial performance of Tevogen Bio, Semper Paratus and the combined company. Forward-looking statements
in this report may be identified by the use of words such as “anticipate,” “assume,” “believe,” “continue,”
“could,” “estimate,” “expect,” “foreseeable,” “future,” “intend,”
“may,” “outlook,” “plan,” “potential,” “proposed” “predict,”
“project,” “seek,” “should,” “target,” “trends,” “will,” “would”
and similar terms and phrases. Forward-looking statements contained in this report include, but are not limited to, statements as to
(i) expectations regarding the Business Combination, including timing for its consummation, (ii) anticipated use of proceeds from the
transaction, (iii) Tevogen Bio’s and Semper Paratus’ expectations as to various operational results and market conditions,
(iv) Tevogen Bio’s anticipated growth strategy, (v) financial condition and performance of Tevogen Bio and Semper Paratus, including
the anticipated benefits, the implied enterprise value, the expected financial impacts of the Business Combination, (vi) the financial
condition, liquidity, results of operations, the products, the expected future performance and market opportunities of Tevogen Bio, (vii)
Tevogen Bio’s ability to obtain and maintain adequate patent protection for its product candidates and ExacTcell and unproven approach
to the development of product candidates using ExacTcell, (viii) the lengthy and time-consuming FDA regulatory approval process, (ix)
Tevogen Bio’s limited operating history and no products approved for commercial sale, (x) anticipated benefits of the Business
Combination, and (xi) expected listing of the combined company.
The
forward-looking statements contained in this report are based on the current expectations of Tevogen Bio, Semper Paratus and their respective
management and are subject to risks and uncertainties. No assurance can be given that future developments affecting Tevogen Bio, Semper
Paratus or the combined company will be those that are anticipated. Actual results may differ materially from current expectations due
to changes in global, regional or local economic, business, competitive, market, regulatory and other factors, many of which are beyond
the control of Tevogen Bio and Semper Paratus. Should one or more of these risks or uncertainties materialize, or should any of the assumptions
prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Factors that
could cause actual results to differ may emerge from time to time, and it is not possible to predict all of them.
Such
factors include, but are not limited to: the risk that the Business Combination may not be completed in a timely manner or at all; the
failure to meet closing conditions; the occurrence of any event, change or other circumstances that could give rise to the termination
of the definitive agreement in respect of the transaction; failure to achieve sufficient cash available (taking into account all available
financing sources) following any redemptions of Semper Paratus’ public shareholders; failure to meet relevant listing standards
in connection with the consummation of the transaction; failure to recognize the anticipated benefits of the transaction, which may be
affected by, among other things, competition, the ability of the combined entity to maintain relationships with customers and suppliers
and strategic alliance third parties, and to retain its management and key employees; potential litigation relating to the proposed transaction;
unexpected costs and expenses related to the transaction; estimates of Tevogen Bio and the combined company’s financial performance
being materially incorrect predictions; changes in general economic or political conditions; changes in the markets that Tevogen Bio
targets or the combined company will target; any change in laws applicable to Semper Paratus or Tevogen Bio or any regulatory or judicial
interpretation thereof; and other factors, risks and uncertainties, including those included under the heading “Risk Factors”
in the Proxy Statement/Prospectus, and other documents to be filed by Semper Paratus from time to time with the SEC. Tevogen Bio and
Semper Paratus caution that the foregoing list of factors is not exhaustive. Any forward-looking statement made in this report speak
only as of the date hereof. Plans, intentions or expectations disclosed in forward-looking statements may not be achieved and no one
should place undue reliance on such forward-looking statements. Neither Tevogen Bio nor Semper Paratus undertake any obligation to update,
revise or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may
be required by any applicable securities laws.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
The
following exhibits are being filed herewith:
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
SEMPER
PARATUS ACQUISITION CORPORATION |
|
|
|
Date:
February 1, 2024 |
By: |
/s/
Surendra Ajjarapu |
|
Name: |
Surendra
Ajjarapu |
|
Title: |
Chairman
and Chief Executive Officer |
Exhibit
99.1
Semper
Paratus Acquisition Corporation’s Shareholders Approve Business Combination with Tevogen Bio
New
York, NY, February 1, 2024 (GLOBE NEWSWIRE) — Semper Paratus Acquisition Corporation (“Semper Paratus”) (Nasdaq:
LGST, LGSTW, LGSTU), a publicly-traded special purpose acquisition company, announced today that its shareholders have approved the proposed
business combination (the “Business Combination”) with Tevogen Bio Inc, a Delaware corporation (“Tevogen Bio”),
at an extraordinary general meeting of Semper Paratus’ shareholders that was held on Wednesday, January 31, 2024 (the “Meeting”).
Each
of the proposals presented at the Meeting was approved, and the Business Combination is expected to be consummated as soon as practicable
following the satisfaction or waiver of the remaining closing conditions described in Semper Paratus’ definitive proxy statement,
which was filed with the U.S. Securities and Exchange Commission (the “SEC”) on January 10, 2024, as supplemented by a Supplement
No. 1 filed on January 24, 2024 and Supplement No. 1 filed on January 24, 2024 (the “Proxy Statement/Prospectus”), including
the condition that the common stock of the combined company will have been approved for listing on a tier of The Nasdaq Stock
Market. Following the closing of the Business Combination, common stock of the combined company is expected to begin trading on Nasdaq
under the symbol “TVGN”.
In
connection with the Meeting, shareholders holding 1,432,457 shares out of a possible 1,502,180 Semper Paratus ordinary shares
(the “Public Shares”) exercised their right to redeem their shares for a pro rata portion of the funds in Semper Paratus’
trust account (the “Trust Account”). The trustee of the Trust Account is calculating the final amount of the funds to be
removed from the Trust Account in connection with such redemptions, but the current preliminary calculations are that approximately $15.9
million (approximately $11.07 per Public Share) will be removed from the Trust Account to pay such holders.
Following
the Meeting, Semper Paratus’ Chief Executive Officer Surendra Ajjarapu stated “We have cleared yet another hurdle to
closing our business combination with Tevogen Bio, and we will continue to work diligently with Tevogen Bio to satisfy the remaining
closing conditions.”
About
Tevogen Bio
Tevogen
Bio is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic
T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases,
cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes
that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science
and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual
property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted
patents and twelve pending patents, two of which are related to artificial intelligence.
Tevogen
Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product
launch experience. Tevogen Bio’s leadership believes that accessible personalized therapeutics are the next frontier of medicine,
and that disruptive business models are required to sustain medical innovation.
About
Semper Paratus
Semper
Paratus is a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition,
stock purchase, reorganization, or similar business combination with one or more businesses. Its principals possess public and private
market investing experience and operational knowledge to bring value added benefits to Tevogen Bio. The Semper Paratus team has substantial
experience investing in and operating businesses in multiple sectors, as well as a significant long-term track record in creatively structuring
transactions to unlock and maximize value.
Cautionary
Statement Regarding Forward-Looking Statements
This
communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended,
that reflect Tevogen Bio’s and Semper Paratus’ current views with respect to, among other things, the future operations and
financial performance of Tevogen Bio, Semper Paratus and the combined company. Forward-looking statements in this communication may be
identified by the use of words such as “anticipate,” “assume,” “believe,” “continue,”
“could,” “estimate,” “expect,” “foreseeable,” “future,” “intend,”
“may,” “outlook,” “plan,” “potential,” “proposed” “predict,”
“project,” “seek,” “should,” “target,” “trends,” “will,” “would”
and similar terms and phrases. Forward-looking statements contained in this communication include, but are not limited to, statements
as to (i) expectations regarding the Business Combination, including timing for its consummation, (ii) anticipated use of proceeds from
the transaction, (iii) Tevogen Bio’s and Semper Paratus’ expectations as to various operational results and market conditions,
(iv) Tevogen Bio’s anticipated growth strategy, (v) financial condition and performance of Tevogen Bio and Semper Paratus, including
the anticipated benefits, the implied enterprise value, the expected financial impacts of the Business Combination, (vi) the financial
condition, liquidity, results of operations, the products, the expected future performance and market opportunities of Tevogen Bio, (vii)
Tevogen Bio’s ability to obtain and maintain adequate patent protection for its product candidates and ExacTcell and unproven approach
to the development of product candidates using ExacTcell, (viii) the lengthy and time-consuming FDA regulatory approval process, (ix)
Tevogen Bio’s limited operating history and no products approved for commercial sale, (x) anticipated benefits of the Business
Combination, and (xi) expected listing of the combined company.
The
forward-looking statements contained in this communication are based on the current expectations of Tevogen Bio, Semper Paratus and their
respective management and are subject to risks and uncertainties. No assurance can be given that future developments affecting Tevogen
Bio, Semper Paratus or the combined company will be those that are anticipated. Actual results may differ materially from current expectations
due to changes in global, regional or local economic, business, competitive, market, regulatory and other factors, many of which are
beyond the control of Tevogen Bio and Semper Paratus. Should one or more of these risks or uncertainties materialize, or should any of
the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements.
Factors that could cause actual results to differ may emerge from time to time, and it is not possible to predict all of them.
Such
factors include, but are not limited to: the risk that the transaction may not be completed in a timely manner or at all; the failure
to meet closing conditions; the occurrence of any event, change or other circumstances that could give rise to the termination of the
definitive agreement in respect of the transaction; failure to achieve sufficient cash available (taking into account all available financing
sources) following any redemptions of Semper Paratus’ public shareholders; failure to meet relevant listing standards in connection
with the consummation of the transaction; failure to recognize the anticipated benefits of the transaction, which may be affected by,
among other things, competition, the ability of the combined entity to maintain relationships with customers and suppliers and strategic
alliance third parties, and to retain its management and key employees; potential litigation relating to the proposed transaction; unexpected
costs and expenses related to the transaction; estimates of Tevogen Bio and the combined company’s financial performance being
materially incorrect predictions; changes in general economic or political conditions; changes in the markets that Tevogen Bio targets
or the combined company will target; any change in laws applicable to Semper Paratus or Tevogen Bio or any regulatory or judicial interpretation
thereof; and other factors, risks and uncertainties, including those included under the heading “Risk Factors” in the Proxy
Statement/Prospectus, and other documents to be filed by Semper Paratus from time to time with the SEC. Tevogen Bio and Semper Paratus
caution that the foregoing list of factors is not exhaustive. Any forward-looking statement made in this communication speak only as
of the date hereof. Plans, intentions or expectations disclosed in forward-looking statements may not be achieved and no one should place
undue reliance on such forward-looking statements. Neither Tevogen Bio nor Semper Paratus undertake any obligation to update, revise
or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required
by any applicable securities laws.
Contacts
Tevogen
Communications
T:
1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
Semper
Paratus Acquisition Corporation
suren@semperparatusspac.com
v3.24.0.1
Cover
|
Jan. 31, 2024 |
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Jan. 31, 2024
|
Entity File Number |
001-41002
|
Entity Registrant Name |
Semper
Paratus Acquisition Corporation
|
Entity Central Index Key |
0001860871
|
Entity Incorporation, State or Country Code |
E9
|
Entity Address, Address Line One |
767
Third Avenue
|
Entity Address, Address Line Two |
38th Floor
|
Entity Address, City or Town |
New York
|
Entity Address, State or Province |
NY
|
Entity Address, Postal Zip Code |
10017
|
City Area Code |
(646)
|
Local Phone Number |
807-8832
|
Written Communications |
true
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
Units Each Consisting Of One Class Ordinary Share Par Value 0. 0001 Per Share And Onehalf Of One Redeemable Warrant [Member] |
|
Title of 12(b) Security |
Units,
each consisting of one Class A ordinary share, par value $0.0001 per share, and one-half of one Redeemable Warrant
|
Trading Symbol |
LGSTU
|
Security Exchange Name |
NASDAQ
|
Class Ordinary Shares Par Value 0. 0001 Per Share Included As Part Of Units [Member] |
|
Title of 12(b) Security |
Class
A ordinary shares, par value $0.0001 per share, included as part of the Units
|
Trading Symbol |
LGST
|
Security Exchange Name |
NASDAQ
|
Redeemable Warrants Each Exercisable For One Class Ordinary Share For 11. 50 Per Share Included As Part Of Units [Member] |
|
Title of 12(b) Security |
Redeemable
warrants, each exercisable for one Class A ordinary share for $11.50 per share, included as part of the Units
|
Trading Symbol |
LGSTW
|
Security Exchange Name |
NASDAQ
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=LGSTU_UnitsEachConsistingOfOneClassOrdinaryShareParValue0.0001PerShareAndOnehalfOfOneRedeemableWarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=LGSTU_ClassOrdinarySharesParValue0.0001PerShareIncludedAsPartOfUnitsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=LGSTU_RedeemableWarrantsEachExercisableForOneClassOrdinaryShareFor11.50PerShareIncludedAsPartOfUnitsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Grafico Azioni Semper Paratus Acquisiti... (NASDAQ:LGSTU)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Semper Paratus Acquisiti... (NASDAQ:LGSTU)
Storico
Da Set 2023 a Set 2024